DMAAU Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 0.21%, SMA50 0.51%, SMA200 0.57%). The stock’s 14-day RSI is 56.88 (neutral), while the ATR of 0.05 points to tighter daily ranges. The stock remains sitting in the mid-range of its 52-week band, trading -6.1% below its high and over 1.6% above its low. Average 10-day trading volume of 9.00 shares is below the 3-month average of 140.47, indicating normal recent market interest.

Our AI price prediction model suggests that Drugs Made In America Acquisition Corp. Units stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

currently trading near 52-week highs band. Valuation shows Drugs Made In America Acquisition Corp. Units trading at a premium to the broader market with a P/E of 55.22.

Drugs Made In America Acquisition Corp. Units (NASDAQ:DMAAU) closed at $10.82 USD, gaining $0.03 (0.28%) from the previous close of $10.79. The stock is currently mid-range between its 52-week high and low $10.30 and $12.50. With a market capitalization of about $355.52 million, Drugs Made In America Acquisition Corp. Units is classified as a small-cap and shows lower-than-market volatility (beta ~0.19). Key stats such as the average daily volume over the past year has been around 667.00 shares, volume is running light vs its 52-week average. Headquartered in New York, NY, Drugs Made In America Acquisition Corp. Units operates in the Financial Services sector and the Shell Companies industry. Led by CEO Roger Bendelac, the company employs approximately 2 people and listed since January 27, 2025. Drugs Made In America Acquisition Corp. operates as a special purpose acquisition company (SPAC).

Dividend and splits history remains an important factor for investors monitoring long-term returns.

Drugs Made In America Acquisition Corp. Units trades at a P/E ratio of 55.22, slightly above the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 1.58 suggesting the stock is closer to book value. The P/FCF stands at -814.41, also below market averages.